Please see our news in the archive to the right.
MIOCA Reaches $500,000 in Research Grants Awarded in Michigan
May 7, 2019
ANN ARBOR, MI - On World Ovarian Cancer Day, the Michigan Ovarian Cancer Alliance (MIOCA) announces an important milestone in its effort to save lives. Since it started giving grants in 2014, MIOCA has now awarded over a half-million dollars to researchers in Michigan who are finding new ways to improve the early detection and treatment of ovarian cancer.
“MIOCA is pleased to announce three 2019 Geri Fournier Ovarian Cancer Research Award winners, who will each receive $50,000 as part of our efforts to forward ovarian cancer research in our state.” said MIOCA Founder and President, Pam Dahlmann. The Award, named for the Founders’ mother who helped establish MIOCA before her death from ovarian cancer in 2011, was created to recognize the critical research happening right here, in our state, which is often underfunded. “Each and every research project we fund has the potential to result in improved understanding of the disease that will hopefully transform lives for women across Michigan and beyond.”
The State of Michigan is fortunate to have several of the nations’ top ovarian cancer researchers, and this year’s winners represent three institutions who are leading the way in ovarian cancer research. This year’s winners are:
• Rebecca Liu, M.D, Saint Joseph Mercy Health System,
University of Michigan Rogel Cancer Center
Michigan Cancer Research Consortium
"EASE: Education, Alliance, Solace, and Empowerment for
Ovarian Cancer Patients."
• Nouri Neamati, Ph.D., University of Michigan College of Pharmacy, and
Karen McLean, M.D., Ph.D., University of Michigan Medical School,
University of Michigan Rogel Cancer Center
"Development of STAT3 inhibitors for the treatment of ovarian cancer."
• John Risinger, Ph.D., Michigan State University
College of Human Medicine
"PARP inhibition and non-BRCA DNA damage repair mutation."
For the entire Press Release, click here.
April 2, 2019
MIOCA often gets news about Clinical Trials. The trials below are in progress and are looking for participants. As a matter of policy, MIOCA does not endorse or recommend any treatment or study. You should always consult with your gynecologic oncologist before starting a clinical trial. Click on the study name for more information.
ATHENA – Rucaparib and Novolumab for Maintenance in Ovarian Cancer
ATHENA is a study for women who are newly diagnosed with ovarian cancer. ATHENA is looking at whether maintenance therapy with a PARP inhibitor and/or immunotherapy improves outcomes for women who have completed front-line ovarian cancer treatment.
GEM – Genetic Education for Men Study
The Genetic Education for Men study is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who received positive BRCA1/2 test results and have at least one untested male relative.
ARIEL4 - Rucaparib and Recurrent Ovarian Cancer
ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information.
WISP - Women Choosing Surgical Prevention
This study is open to pre-menopausal women between 30-50 with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, PMS2 or EPCAM. Women choose to either have their fallopian tubes removed now and their ovaries later or to have their tubes and ovaries removed at the same time. Outcomes are sexual function and quality of life between the women grouped by surgical procedure.
MAGENTA - MAking GENetic Testing Accessible
The MAGENTA study is open to women 30 years of age or older who may be at increased risk to develop ovarian cancer based on their personal or family history. Participants who qualify for this study will undergo genetic testing (using a saliva sample) for 19 genes associated with inherited cancer risk (including BRCA1 and BRCA2), and complete a series of online questionnaires regarding their experience. Some individuals in this study will undergo genetic counseling over the phone; others will not. Participation in this trial will not require any travel, but will require access to the internet and phone.